Lemerond Nicole 4

What Happened

• Nicole Lemerond, a director of GeoVax Labs, received a grant/award of 6,000 derivative shares on June 17, 2026. The reported acquisition price is $0.00, and the transaction is listed as a derivative award (transaction code A). No cash was paid for the shares; reported value for the filing is $0.00.
• This transaction is an award (compensation/benefit), not an open-market purchase or sale. Such grants are commonly part of director compensation and do not directly signal a buy or sell decision in the market.

Key Details

• Transaction date: 2026-06-17; Filing date (Form 4): 2026-06-22.
• Amount: 6,000 shares acquired; reported price: $0.00; reported transaction value: $0.00.
• Transaction code: A (grant/award/other acquisition); security treated as derivative in filing.
• Shares owned after the transaction: not specified in the provided filing details.
• Filing timeliness: Filed five days after the transaction—Form 4s are generally due within two business days, so this appears to be a late filing (may be marked late on EDGAR).

Context

• Director awards are typically part of routine compensation (restricted stock, RSUs, or similar). They differ from open-market purchases, which some investors view as a stronger personal investment signal.
• Derivative awards often carry vesting schedules or restrictions; the filing did not detail vesting or whether shares are immediately transferable.